Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Alnylam Pharmaceuticals I...

    NASDAQ: ALNY · Real-Time Price · USD
    307.82
    3.15 (1.03%)
    At close: Jun 13, 2025, 3:59 PM
    303.31
    -1.47%
    After-hours: Jun 13, 2025, 04:57 PM EDT
    1.03%
    Bid 297.17
    Market Cap 40.14B
    Revenue (ttm) 2.35B
    Net Income (ttm) -269.7M
    EPS (ttm) -2.1
    PE Ratio (ttm) -146.58
    Forward PE 168.7
    Analyst Buy
    Ask 309
    Volume 410,923
    Avg. Volume (20D) 1,043,847
    Open 300.97
    Previous Close 304.67
    Day's Range 301.64 - 307.86
    52-Week Range 152.30 - 310.22
    Beta 0.21

    About ALNY

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ALNY
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ALNY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 months ago
    +2.6%
    Alnylam Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription
    2 months ago
    +11.75%
    Alnylam Pharmaceuticals shares are trading higher after the company secured FDA approval pf sNDA for its RNAi therapeutic, AMVUTTRA ,for treatment of ATTR-CM in adults.
    news image

    4 days ago · zacks.com

    Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM

    ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

    news image

    5 days ago · businesswire.com

    Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted...

    news image

    2 weeks ago · businesswire.com

    Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman S...

    news image

    3 weeks ago · fool.com

    3 High-Flying Stocks That Could Soar Even More

    Many investors love the "big mo." That's short for "big momentum.

    news image

    4 weeks ago · businesswire.com

    AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of ...

    news image

    1 month ago · businesswire.com

    Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship ...

    news image

    1 month ago · businesswire.com

    Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Secu...

    news image

    1 month ago · zacks.com

    Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y

    ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.

    news image

    1 month ago · seekingalpha.com

    Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Christine Lindenboom – Chief Corporate Communications Officer Yvonne Greenstre...

    news image

    1 month ago · zacks.com

    Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics

    While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare t...

    Add to Watchlist